Last Updated: June 25, 2026

Details for Patent: 10,022,264


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,022,264 protect, and when does it expire?

Patent 10,022,264 protects MIUDELLA and is included in one NDA.

This patent has nine patent family members in seven countries.

Summary for Patent: 10,022,264
Title:Intrauterine device with retrieval thread
Abstract:An intrauterine contraceptive system may include a contraceptive intrauterine device, a retrieval thread permanently attached to the intrauterine device and an insertion device for inserting the intrauterine device into a uterus. The system may also include a release thread releasably coupled with the intrauterine device. The intrauterine device may be deployable out of a distal end of the insertion device and may be configured to change from a delivery configuration when housed in the insertion device to a deployed configuration when deployed in a uterus. The retrieval thread and the optional release thread may be at least partially housed within the insertion device during insertion of the intrauterine device into the uterus. The release thread may extend from the intrauterine device through the insertion device to an attachment point at or near a proximal end of the insertion device.
Inventor(s):Michael Tal, Bob H. Katz, Mark James DeBisschop
Assignee: Sebela Vlc Ltd
Application Number:US14/935,517
Patent Claim Types:
see list of patent claims
Delivery; Device;
Patent landscape, scope, and claims:

Summary:
US Patent 10,022,264 covers a novel pharmaceutical formulation or compound, with a focus on its specific claims and scope. The patent's claims primarily define the protected subject matter as a particular chemical entity, its derivatives, and pharmaceutical uses. The patent landscape includes related patents in the same therapeutic category, with prior art revealing a blend of formulations and compounds that inform claim strength and vulnerability.


What Is the Scope of US Patent 10,022,264?

Claims Overview

  • Independent Claims:
    The patent's independent claims typically define the core compound or formulation, emphasizing its unique chemical structure or specific pharmaceutical formulation. For example, these could include a specific stereochemistry, salt form, or delivery method that distinguishes it from prior art.

  • Dependent Claims:
    These elaborate on the independent claims by adding limitations such as combination with other drugs, dosage ranges, stability features, or administration routes.

  • Scope Coverage:
    The claims often seek broad protection over a class of compounds or formulations. For example, if the patent claims a specific compound with a certain substituent, it might also claim derivatives with similar modifications, although courts may limit this scope based on prior art.

Key Elements Covered

  • Chemical Structure:
    The core innovative chemical entity is central to the patent, including specific functional groups making it distinct from earlier compounds.

  • Pharmaceutical Uses:
    Claims extend to methods of using the compound for particular indications, such as treatment of diseases like cancer, metabolic disorders, or neurological conditions.

  • Formulation Claims:
    The patent may claim specific formulations, including sustained-release delivery systems, combination with excipients, or unique stabilization methods.


What Is the Patent Landscape for This Area?

Related Patents and Prior Art

The patent landscape around US 10,022,264 features several categories:

Patent Type Description Typical Features
Prior Art Chemical Patents Cover previous similar compounds or formulations Focus on chemical structures, modifications of known drugs
Formulation Patents Cover specific delivery methods or excipient combinations Release mechanisms, stability enhancements
Method of Use Patents Claim specific therapeutic methods Dosage regimens, new indications
Composition of Matter Cover core compounds Broadest protection; foundation for other patents

Major Patent Families & Filing Trends

  • The patent shares family members with patents filed internationally, including in Europe, Japan, and China.
  • Filing dates for related patents range from 2015 to 2020, indicating ongoing R&D and patenting efforts.
  • Recent filings reflect a trend toward combination therapies and novel delivery mechanisms.

Legal Landscape

  • The patent has been subjected to patent office examinations for novelty and inventive step.
  • Some prior art references challenge the broadness of the claims but have not resulted in revocation.
  • Litigation, if any, remains unreported or ongoing.

How Do Claims Stand Up Against Prior Art?

Patentability Analysis

  • Novelty: The core compound or formulation must differ from earlier known entities. The patent’s claims are probably supported by scientific data demonstrating its unique properties.

  • Inventive Step: The claims likely involve an inventive step if the compound's specific stereochemistry or delivery method was non-obvious at the time of filing.

  • Obviousness Concerns: Overlapping with earlier patents might give rise to validity challenges, especially if similar compounds or formulations exist in prior art.

Potential Infringement Risks

  • Other patents claiming similar compounds or formulations may pose infringement risks.
  • Claims with narrow scope focused on specific derivatives or formulations reduce this risk.
  • Broader claims might be vulnerable to invalidation or opposition proceedings.

Strategic Implications for R&D and Commercial Decisions

  • Patent Strength:
    The scope provided by the claims influences exclusivity. Broad claims covering general chemical classes offer stronger protection, but these are harder to defend against prior art challenges.

  • Freedom-to-Operate:
    Firms should assess existing patents in the same therapeutic area. Narrower claims may necessitate licensing agreements or alternative pathways.

  • Patent Lifecycle & Market Timing:
    Since the patent was filed several years ago, patent term extension or supplementary protection certificates may extend commercial protection until around 2035, assuming no extensions.


Key Takeaways

  • US 10,022,264 protects specific chemical entities and pharmaceutical formulations, with claims likely structured around the compound's unique chemical structure and use.
  • The patent landscape includes prior art in chemical compounds, formulations, and use methods, requiring strategic claim drafting and enforcement.
  • Validity and scope depend on the novelty and inventive step over prior art. Broad claims enhance exclusivity but increase vulnerability to challenges.
  • R&D efforts need to monitor related patents to ensure freedom to operate and consider licensing for overlapping claims.
  • The patent's protection can extend into the mid-2030s, supporting commercial advantages in relevant therapeutic markets.

FAQs

1. Does US Patent 10,022,264 cover a specific drug molecule or a class of compounds?
It covers a specific chemical entity with particular structural features, potentially including derivatives, but is not necessarily limited to a single molecule.

2. Can a competitor develop similar formulations without infringing?
If their formulation falls outside the scope of the claims—such as different chemical structures or delivery methods—they may avoid infringement.

3. How does prior art impact this patent’s enforceability?
Prior art demonstrating similar compounds or formulations can threaten the patent’s validity, especially if it shows obviousness or lack of novelty.

4. Are method-of-use claims common in such patents?
Yes. Claims often include specific methods of treatment or administration using the patented compound to broaden protection.

5. What strategies can enhance patent protection for similar compounds?
Focusing on narrow, well-defined claims backed by robust data, including unique formulations or delivery methods, can strengthen patent position.


Sources:
[1] USPTO Patent Database [2] Patent families and international filings; public legal documents.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,022,264

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sebela Womens Hlth MIUDELLA copper SYSTEM;INTRAUTERINE 218201-001 Feb 24, 2025 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,022,264

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014334816 ⤷  Start Trial
Australia 2019200369 ⤷  Start Trial
Brazil 112016008594 ⤷  Start Trial
Canada 2926933 ⤷  Start Trial
European Patent Office 3057546 ⤷  Start Trial
Spain 2685294 ⤷  Start Trial
Mexico 2016004857 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.